Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Asia Congress 2022

Tumour-agnostic precision therapeutics: What is the way forward? (In collaboration with National Societies)

Implementing NGS multiplex testing for actionable biomarkers in solid tumours

Date

01 Dec 2022

Session

Tumour-agnostic precision therapeutics: What is the way forward? (In collaboration with National Societies)

Topics

Cancer Biology;  Cancer Registries;  Cancer Care Equity Principles and Health Economics;  Cancer Diagnostics

Tumour Site

Presenters

Hsiang-Fong Kao

Authors

H. Kao

Author affiliations

  • Medical Oncology, NTUH - National Taiwan University Hospital, 10002 - Taipei City/TW

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.